Shijiazhuang No.4 Pharmaceutical Co., Ltd.
-
Founded in:
1994-06-28 -
Country:
China -
Address:
No. 518, Huaian East Road, Shijiazhuang High-tech Industrial Development Zone -
Tax NO.:
911301001044060055 -
Registered Funds:
950 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Betastatin hydrochloride |
H1 receptor agonist, has a significant dilating effect on cerebrovascular and cardiovascular systems, especially the conical artery system, significantly increases the flow of heart, brain and peripheral circulation, improves blood circulation, and lowers systemic blood pressure; increases cochlear and vestibular blood flow, eliminates ear vertigo, tinnitus and ear closure; increases capillary permeability, promotes extracellular fluid absorption, and eliminates lymphatic edema; counteracts the vasoconstrictive effect of catecholamines and lowers arterial pressure, inhibits blood coagulation and ADP-induced platelet aggregation, and prolongs the time of thrombosis in vitro in rats; has a slight diuretic effect.
More
H1 receptor agonist, has a significant dilating effect on cerebrovascular and cardiovascular systems, especially the conical artery system, significantly increases the flow of heart, brain and peripheral circulation, improves blood circulation, and lowers systemic blood pressure; increases cochlear and vestibular blood flow, eliminates ear vertigo, tinnitus and ear closure; increases capillary permeability, promotes extracellular fluid absorption, and eliminates lymphatic edema; counteracts the vasoconstrictive effect of catecholamines and lowers arterial pressure, inhibits blood coagulation and ADP-induced platelet aggregation, and prolongs the time of thrombosis in vitro in rats; has a slight diuretic effect. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Metronidazole |
It has a strong antibacterial effect on most anaerobic bacteria, but has no effect on aerobic bacteria and facultative anaerobes. The antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus, etc. Actinomycetes, Lactobacillus and Propionibacterium are resistant to it. It can also inhibit the redox reaction of amoeba and break the nitrogen chain of protozoa. It has a strong effect of killing trichomonas, and its mechanism is unknown. It is carcinogenic to some animals.
More
It has a strong antibacterial effect on most anaerobic bacteria, but has no effect on aerobic bacteria and facultative anaerobes. The antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus, etc. Actinomycetes, Lactobacillus and Propionibacterium are resistant to it. It can also inhibit the redox reaction of amoeba and break the nitrogen chain of protozoa. It has a strong effect of killing trichomonas, and its mechanism is unknown. It is carcinogenic to some animals. |
443-48-1 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium chloride |
Replenish the body's necessary water and electrolytes
More
Replenish the body's necessary water and electrolytes |
1.75g | 7647-14-5 | 43 |
| Potassium chloride |
Replenish the body's necessary water and electrolytes
More
Replenish the body's necessary water and electrolytes |
1.50g | 7447-40-7 | 39 |
| Sodium lactate |
Replenish the body's necessary water and electrolytes
More
Replenish the body's necessary water and electrolytes |
2.24g | 312-85-6 | 0 |
| GLUCOSE |
The maintenance infusion is prepared with 10% glucose, and its electrolyte composition is calculated based on the average water and electrolyte requirements of the normal human body.
More
The maintenance infusion is prepared with 10% glucose, and its electrolyte composition is calculated based on the average water and electrolyte requirements of the normal human body. |
100g | 58367-01-4 | 15 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium lactate |
The final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid.
More
The final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid. |
3.10g | 312-85-6 | 0 |
| Sodium chloride |
[Pharmacology and Toxicology] Under normal circumstances, there is also a small amount of lactic acid in the human blood, which is mainly generated by glucose or glycogenolysis, from muscles, skin, brain and cells, etc. After lactic acid is generated, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the terminal metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. [Pharmacokinetics] The pH of sodium lactate is 6.5-7.5. It is quickly absorbed after oral administration, oxidized by the liver within 1-2 hours, and metabolized into sodium bicarbonate, but it is generally commonly used for intravenous injection. Using sodium lactate instead of sodium acetate as a buffer for peritoneal dialysis fluid can reduce peritoneal irritation, and the effects on cardiac inhibition and peripheral vascular resistance can also be reduced.
More
[Pharmacology and Toxicology] Under normal circumstances, there is also a small amount of lactic acid in the human blood, which is mainly generated by glucose or glycogenolysis, from muscles, skin, brain and cells, etc. After lactic acid is generated, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the terminal metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. [Pharmacokinetics] The pH of sodium lactate is 6.5-7.5. It is quickly absorbed after oral administration, oxidized by the liver within 1-2 hours, and metabolized into sodium bicarbonate, but it is generally commonly used for intravenous injection. Using sodium lactate instead of sodium acetate as a buffer for peritoneal dialysis fluid can reduce peritoneal irritation, and the effects on cardiac inhibition and peripheral vascular resistance can also be reduced. |
6.00g | 7647-14-5 | 43 |
| Potassium chloride |
When hyperkalemia is accompanied by acidosis, sodium lactate can correct the acidosis and allow potassium ions to enter the cells from the blood and extracellular fluid.
More
When hyperkalemia is accompanied by acidosis, sodium lactate can correct the acidosis and allow potassium ions to enter the cells from the blood and extracellular fluid. |
0.30g | 7447-40-7 | 39 |
| Calcium chloride |
[Pharmacology and Toxicology] Under normal circumstances, there is also a small amount of lactic acid in the human blood, which is mainly generated by glucose or glycogenolysis, from muscles, skin, brain and cells, etc. After lactic acid is generated, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the terminal metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. [Pharmacokinetics] The pH of sodium lactate is 6.5-7.5. It is quickly absorbed after oral administration, oxidized by the liver within 1-2 hours, and metabolized into sodium bicarbonate, but it is generally commonly used for intravenous injection. Using sodium lactate instead of sodium acetate as a buffer for peritoneal dialysis fluid can reduce peritoneal irritation, and the effects on cardiac inhibition and peripheral vascular resistance can also be reduced.
More
[Pharmacology and Toxicology] Under normal circumstances, there is also a small amount of lactic acid in the human blood, which is mainly generated by glucose or glycogenolysis, from muscles, skin, brain and cells, etc. After lactic acid is generated, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the terminal metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. [Pharmacokinetics] The pH of sodium lactate is 6.5-7.5. It is quickly absorbed after oral administration, oxidized by the liver within 1-2 hours, and metabolized into sodium bicarbonate, but it is generally commonly used for intravenous injection. Using sodium lactate instead of sodium acetate as a buffer for peritoneal dialysis fluid can reduce peritoneal irritation, and the effects on cardiac inhibition and peripheral vascular resistance can also be reduced. |
0.2g | 10043-52-4 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ambroxol hydrochloride |
This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.
More
This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up. |
23828-92-4 | 38 |